Launched Krestin (Poly-saccharide-K) in Japan to treat gastrointestinal, lung and breast cancer
Launched the first natural-type interferon beta preparations for brain tumour and skin cancer in Japan
Received approval of irinotecan, the first chemotherapy to demonstrate survival benefits in colorectal cancer1
Launched denosumab in Japan for treatment of bone complications of multiple myeloma and bone metastases of solid tumours
>20 compounds in development directed at a range of diseases with unmet medical needs, with a focus on ADC technology
In January 2021, trastuzumab deruxtecan received EMA approval for HER2-positive metastatic breast cancer in the EU2
Trastuzumab deruxtecan received approval for second line therapy in the EU3
We have more than 40 years of experience in cancer treatment, innovations and research!
1 Douillard JY, Clin Col Can. 2005,; 5 (S1): S34-S37.
2 Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens SmPC at www.ema.europa.eu.
3 Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. SmPC at www.ema.europa.eu.